Arthur Mourtzinos, MD
Urology · Burlington, MANPI 1649238577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,623 of the $42,575 with a category attached, or 76.6%. Medtronic accounts for 74.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $11,284 and has fallen 67.9% since, to $3,628 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $208.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$32K
- Boston Scientific$7K
- Neotract Inc.$914
- Astellas Pharma US Inc$497
- AbbVie$441
- Procept Biorobotics Corporation$439
- plus $1K from 12 others
Across 13 payments — averaging $1306.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$11K
- Sumitomo Pharma America, Inc.$6K
What the payments were for
- Speaking & faculty fees$32,62377%
- Travel & lodging$3,8789%
- Food & beverage$5,97514%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 72 | $31,904 |
| Boston Scientific | 12 | $6,982 |
| Neotract Inc. | 9 | $914 |
| Astellas Pharma US Inc | 20 | $497 |
| AbbVie(2 entities) | 15 | $441 |
| Procept Biorobotics Corporation | 4 | $439 |
| Ambu Inc. | 5 | $266 |
| Dentsply IH Inc. | 24 | $266 |
| C. R. Bard, Inc. & Subsidiaries | 14 | $214 |
| Rochester Medical Corporation | 14 | $165 |
| Urovant Sciences Inc | 3 | $147 |
| Ferring Pharmaceuticals Inc. | 4 | $97 |
| Teleflex LLC | 1 | $93 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Caldera Medical, Inc | 2 | $38 |
| Olympus America Inc. | 1 | $27 |
| Coloplast | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$29,178
- AMS 800 Artificial Urinary Sphincter$6,328
- ALTAVIVA$1,004
- UroLift$825
- AquaBeam Robotic System$379
- AMS 700$282
- GEMTESA$107
How this compares
$42,575 in reported general payments places this provider in the 90th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 147 | $97,209 |
| GemtesaVibegron | 35 | $30,907 |
| Methenamine Hippurate | 450 | $26,416 |
| Trospium Chloride | 252 | $14,169 |
| Mirabegron ErMirabegron | 22 | $10,757 |
| Tamsulosin Hcl | 455 | $9,277 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 198 | $4,446 |
| Finasteride | 241 | $3,562 |
| Estradiol | 43 | $2,820 |
| Oxybutynin Chloride ErOxybutynin Chloride | 83 | $1,966 |
| Trimethoprim | 65 | $1,741 |
| Silodosin | 20 | $1,392 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 92 | $1,280 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 24 | $727 |
| Hydroxyzine Hcl | 32 | $672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $497 | $97,209147 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $53 | $30,90735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 327 urology providers in Massachusetts.
Other urology in Burlington
- Michael CallegariBurlington$53K
- Peris CastanedaBurlington$51K
- William du CombBurlington$9K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.